EFPIA Archives -

New IFPMA and EFPIA guidance on use of social media by the pharmaceutical industry

mike.hammerton@pharmaphorum.com digital channels, EFPIA, HCOs, HCPs, IFPMA, medicines promotion, patient organisations, prescription-only medicines, Regulations, social media 0 Comment

On 28 September 2022, the international and European self-regulatory bodies for the research-based pharmaceutical industry (IFPMA, the International

New IFPMA and EFPIA guidance on use of social media by the pharmaceutical industry

https://pharmaphorum.com/views-and-analysis/new-ifpma-and-efpia-guidance-on-use-of-social-media-by-the-pharmaceutical-industry/

Market Access/ Oncology/ Views & Analysis/ Views & Analysis/ Views and analysis

Are timely access and robust safety mutually exclusive?

Amanda Barrell EFPIA, ema, fda, Kristina Jenei, Oncology 0 Comment

The FDA approves new cancer treatments in half the time of the EMA – but does faster mean

Are timely access and robust safety mutually exclusive?

https://pharmaphorum.com/market-access-2/are-timely-access-and-robust-safety-mutually-exclusive/

Digital/ Sales and Marketing/ Views & Analysis/ Views & Analysis/ Views and analysis

Top 5 takeaways from international hybrid and virtual meeting guidance for pharma

Amanda Barrell EFPIA, IFPMA, pharma, PhRMA, remote meetings, virtual meetings 0 Comment

The move to online international meetings has left pharma companies with uncertainty around contact compliance. But new joint

Top 5 takeaways from international hybrid and virtual meeting guidance for pharma

https://pharmaphorum.com/digital/top-5-takeaways-from-international-hybrid-virtual-meeting-guidance/

News

Drugmakers pledge shorter launch times for drugs in EU

Phil Taylor access, EFPIA, EU, inequality, Value-based pricing 0 Comment

Pharmaceutical companies have said they will try to carve months off the time between approval and launch for

Drugmakers pledge shorter launch times for drugs in EU

https://pharmaphorum.com/news/drugmakers-pledge-shorter-launch-times-for-drugs-in-eu/

Views and analysis

Innovation and access: Improving Europe’s pharmaceutical regulatory framework

Amanda Barrell EFPIA, Innovation, market access, regulation, regulatory approval 0 Comment

EMA “lags behind” other international regulators when it comes to approval timelines, finds EFPIA analysis. Only a regulatory

Innovation and access: Improving Europe’s pharmaceutical regulatory framework

https://pharmaphorum.com/views-and-analysis/innovation-and-access-improving-europes-pharmaceutical-regulatory-framework/

Patients/ Views & Analysis/ Views and analysis

UK-wide whole genome sequencing for newborns is feasible – but there are some key questions to answer first

mike.hammerton@pharmaphorum.com AstraZeneca, COVID-19, EFPIA, healthcare, HTA, NICE, sustainable healthcare 0 Comment

Genomics England, the Department of Health and Social Care’s genome-sequencing hub, has this year announced that support for

UK-wide whole genome sequencing for newborns is feasible – but there are some key questions to answer first

https://pharmaphorum.com/patients/public-approval-whole-genome-sequencing-newborn-screenings-uk-wide-rollout/

R&D/ Views & Analysis/ Views and analysis

Legal requirement, ethical duty: How to develop compliant, useful lay summaries

Amanda Barrell Boehringer Ingelheim, clinical trials, EFPIA, GLP, medical writing 0 Comment

New lay summary guidelines walk sponsors through their obligations under EU regulation No. 536/2014, due to come into

Legal requirement, ethical duty: How to develop compliant, useful lay summaries

https://pharmaphorum.com/r-d/eu-regulation-develop-compliant-lay-summaries/

Patients/ Views & Analysis/ Views and analysis

What does the future of European healthcare look like?

Amanda Barrell AstraZeneca, COVID-19, EFPIA, healthcare, HTA, NICE, sustainable healthcare 0 Comment

After the “stress test” of COVID, how can the sector create resilient, sustainable healthcare systems for the long

What does the future of European healthcare look like?

https://pharmaphorum.com/patients/what-does-the-future-of-european-healthcare-look-like/

Creating a successful and productive partnership

Sales and Marketing/ Views & Analysis/ Views and analysis

EFPIA: Partnership is the key to healthcare’s biggest challenges

Amanda Barrell EFPIA, Janssen, Karolinska Institutet, Novartis, Partnerships, Pfizer 0 Comment

The European pharma body’s new Health Collaboration Guide hopes to inspire greater partnership working across healthcare, showcasing award-winning

EFPIA: Partnership is the key to healthcare’s biggest challenges

https://pharmaphorum.com/sales-marketing/efpia-pharma-healthcare-partnership-guide/

Trending

EFPIA

Login